Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Dihydralazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | MAOA | P21397 | 2/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | GOT1 | P17174 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydralazine SCHEMBL1374523 | 0.94 | ALDH1A1 (0.75) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| Dihydralazine SCHEMBL29794531 | 0.94 | ALDH1A1 (0.75) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| Dihydralazine SCHEMBL28451578 | 0.92 | ALDH1A1 (0.72) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| Dihydralazine SCHEMBL29950602 | 0.92 | ALDH1A1 (0.72) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| Dihydralazine SCHEMBL149629 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| Dihydralazine SCHEMBL29484435 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| Dihydralazine SCHEMBL3462832 | 0.81 | ALDH1A1 (0.90) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| SCHEMBL19358618 | 0.78 | MAPT (0.75) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| SCHEMBL7413898 | 0.78 | ALDH1A1 (0.75) | ALDH1A1MAPTMAOAPTGS1TDP1 | |
| SCHEMBL9748186 | 0.76 | ALDH1A1 (0.53) | ALDH1A1MAPTMAOAPTGS1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578210-A1 | Rottlerin for the treatment of pulmonary hypertension and related diseases and disorders | ATB Innovation Ltd. (DE) | 2013-04-10 | — | — | EP | claimed |
| CN-102627612-A | Two novel dihydralazine sulphate pharmaceutical co-crystals and preparation method thereof | JILIN SANSHANEN TECHNOLOGY DEV CO LTD | 2012-08-08 | — | — | CN | claimed |
| US-20250099551-A1 | THERMOSTABLE FORMULATION OF A21G HUMAN INSULIN | ADOCIA (FR) | 2025-03-27 | — | — | US | disclosed |
| CN-115916155-A | Pharmaceutical composition in the form of an injectable aqueous solution comprising at least a fast-acting insulin analogue and a glucagon inhibitor with a prandial effect | 阿道恰公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115803008-A | Pharmaceutical composition in the form of an injectable aqueous solution comprising at least a fast-acting insulin analogue and a glucagon inhibitor with a prandial effect | 阿道恰公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20210315977-A1 | THERMOSTABLE FORMULATION OF A21G HUMAN INSULIN | ADOCIA (FR) | 2021-10-14 | — | — | US | disclosed |
| CN-112584854-A | Thermostable formulations of A21G human insulin | 阿道恰公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-111683675-A | Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer | 阿道恰公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111670042-A | Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer | 阿道恰公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-109046007-A | A kind of composition for administering gaseous acrolein | 福建皓尔宝新材料科技有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-1951210-B1 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | RECRO GAINESVILLE LLC (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-1948135-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | Elan Pharma International Limited (IE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053392-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053393-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070098796-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride | ALKERMES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070098791-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | ALKERMES, INC. | 2007-05-03 | — | — | US | disclosed |
| CN-1255194-C | Pharmaceutical administration form | MUELLER D (DE) | 2006-05-10 | — | — | CN | disclosed |
| CN-1224366-A | Pharmaceutical administration form | MUELLER D (DE) | 1999-07-28 | — | — | CN | disclosed |
| EP-0907388-A1 | PHARMACEUTICAL ADMINISTRATION FORM | Müller, Dieter (DE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998000198-A1 | PHARMACEUTICAL ADMINISTRATION FORM | MUELLER DIETER (DE) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098796-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride | HRH2, IDH1, IDH2 | ALDH1A1 1047/4885MAPT 2352/4885MAOA 2234/4885 |
| US-20070098791-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | SLC5A11, ATP2A1, QDPR | ALDH1A1 1074/4885MAPT 2062/4885MAOA 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.